Kairos Pharma, LTD. - 8-K Filing Summary
Business Context and Reporting Period
Company: Kairos Pharma, LTD.
Filing Date: September 20, 2024 (Event Date)
Reporting Period: Current Report (Form 8-K)
Business Focus: Clinical development of carotuximab (ENV105) for lung cancer and castrate-resistant prostate cancer.
Key Financial Metrics
This filing reports a specific contractual commitment rather than periodic financial performance. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
- Contractual Commitment: $900,000 payable to PreCheck Health Services, Inc. for bioassay services.
Material Changes
The primary material change is the entry into a definitive agreement on September 20, 2024, with PreCheck Health Services, Inc. This agreement facilitates biomarker screening for the Company's ongoing clinical trials (NCT05401110 and NCT05534646) using PreCheck's SolidTumorCheck+ platform.
Outlook, Risks, and Management Commentary
Strategic Initiative: The agreement aims to identify suitable patients for Phase 1 lung cancer trials and Phase 2 castrate-resistant prostate cancer trials. PreCheck will develop a companion diagnostic involving a three-gene PCR analysis or other genetic analysis for FDA submission.
Risks/Contingencies: Success depends on the development and FDA submission of the companion diagnostic and the efficacy of the biomarker screening in identifying patients for the ENV105 trials.
Investor Verification Checklist
- Verify the full terms of the Bioassay Services Agreement (Exhibit 10.1) for payment milestones and termination clauses.
- Confirm the status of clinical trials NCT05401110 and NCT05534646 on ClinicalTrials.gov.
- Assess the Company's current cash position to ensure the $900,000 commitment does not impact liquidity for ongoing operations.
- Monitor future filings regarding the development timeline and FDA submission status of the companion diagnostic.